Unlike THC, which directly activates CB1 receptors and causes a “high,” CBD does not bind strongly to CB1 or CB2 receptors. Instead, it works indirectly to support and modulate the ECS:
Inhibits FAAH enzyme: By blocking the enzyme that breaks down anandamide, CBD increases levels of this "bliss molecule," enhancing mood and reducing anxiety.
Modulates receptor activity: CBD acts as a negative allosteric modulator of CB1, changing its shape so it responds less to THC—this explains CBD’s ability to reduce THC’s psychoactive effects.
Interferes with transport proteins: CBD competes with endocannabinoids for fatty acid binding proteins (FABPs), slowing their cellular uptake and prolonging their activity.
These mechanisms allow CBD to "tune" the ECS without overstimulating it, promoting balance rather than altering perception.
